News Agency
The Times

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update

  • Written by PR Newswire
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update

Highlights

Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints.

UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report results mid-2024.

SYDNEY, Sept. 26, 2023 /PRNewswire/ --

XanaM...

Read more: Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion